Potential use of biomarkers in oncology
Biomarkers have many potential applications in oncology, including risk assessment, screening, differential diagnosis, determination of prognosis, prediction of response to treatment, and monitoring of disease progression.1
Why test PD-L1?
PD-L1 expression is a potential biomarker, which has been studied in multiple tumour types in recent years.2
Knowing the expression level of PD-L1 in a tumour may provide additional evidence to support a physician when determining the appropriate therapeutic treatment strategy for individual patients.3,4 This knowledge may also facilitate discussions between the physician and patient on the potential benefits and risks of different treatment options.4
PD-L1 expression status adds to the dossier of information available to physicians for any individual patient when making a treatment decision.3–8